Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Kaposi Sarcoma HELP
Based on 1,988 articles published since 2008
||||

These are the 1988 published articles about Sarcoma, Kaposi that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline [Radiotherapy of skin cancers]. 2016

Hennequin, C / Rio, E / Mahé, M-A. ·Service de cancérologie-radiothérapie, hôpital Saint-Louis, 1, avenue Claude-Vellefeaux, 75475 Paris, France. Electronic address: christophe.hennequin2@aphp.fr. · Institut de cancérologie de l'Ouest-René-Gauducheau, boulevard Jacques-Monod, 44805 Saint-Herblain, France. ·Cancer Radiother · Pubmed #27522189.

ABSTRACT: The indications of radiotherapy for skin cancers are not clearly defined because of the lack of randomised trials or prospective studies. For basal cell carcinomas, radiotherapy frequently offers a good local control, but a randomized trial showed that surgery is more efficient and less toxic. Indications of radiotherapy are contra-indications of surgery for patients older than 60, non-sclerodermiform histology and occurring in non-sensitive areas. Adjuvant radiotherapy could be proposed to squamous cell carcinomas, in case of poor prognostic factors. Dose of 60 to 70Gy are usually required, and must be modulated to the size of the lesions. Adjuvant radiotherapy seems beneficial for desmoplastic melanomas but not for the other histological types. Prophylactic nodal irradiation (45 to 50Gy), for locally advanced tumours (massive nodal involvement), decreases the locoregional failure rate but do not increase survival. Adjuvant radiotherapy (50 to 56Gy) for Merckel cell carcinomas increases also the local control rate, as demonstrated by meta-analysis and a large epidemiological study. Nodal areas must be included, if there is no surgical exploration (sentinel lymph node dissection). Kaposi sarcomas are radiosensitive and could be treated with relatively low doses (24 to 30Gy). Also, cutaneous lymphomas are good indications for radiotherapy: B lymphomas are electively treated with limited fields. The role of total skin electron therapy for T-lymphomas is still discussed; but palliative radiotherapy is very efficient in case of cutaneous nodules.

2 Guideline British HIV Association guidelines for HIV-associated malignancies 2014. 2014

Bower, Mark / Palfreeman, A / Alfa-Wali, Maryam / Bunker, Chris / Burns, Fiona / Churchill, Duncan / Collins, Simon / Cwynarski, Kate / Edwards, Simon / Fields, Paul / Fife, Kate / Gallop-Evans, Eve / Kassam, Shireen / Kulasegaram, Ranjababu / Lacey, Charles / Marcus, Robert / Montoto, Sylvia / Nelson, Mark / Newsom-Davis, Tom / Orkin, Chloe / Shaw, Kate / Tenant-Flowers, Melinda / Webb, Andrew / Westwell, Sarah / Williams, Matt / Anonymous110785. · ·HIV Med · Pubmed #24528810.

ABSTRACT: -- No abstract --

3 Guideline British HIV Association guidelines for HIV-associated malignancies 2008. 2008

Bower, M / Collins, S / Cottrill, C / Cwynarski, K / Montoto, S / Nelson, M / Nwokolo, N / Powles, T / Stebbing, J / Wales, N / Webb, A / Anonymous6960605. ·Department of Oncology, Chelsea & Westminster Hospital, London, UK. m.bower@imperial.ac.uk ·HIV Med · Pubmed #18705759.

ABSTRACT: -- No abstract --

4 Guideline Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. 2008

Ljungman, P / de la Camara, R / Cordonnier, C / Einsele, H / Engelhard, D / Reusser, P / Styczynski, J / Ward, K / Anonymous2670602. ·Department of Hematology, Karolinska University Hospital/Huddinge, Stockholm, Sweden. Per.Ljungman@ki.se ·Bone Marrow Transplant · Pubmed #18587440.

ABSTRACT: These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.

5 Editorial HIV and Heart Disease: What Cardiologists Should Know. 2016

Boccara, Franck / Cohen, Ariel. ·Service de Cardiologie, Hôpital Saint-Antoine (AP-HP), Paris 06 - Université Pierre et Marie Curie, Sorbonne Universités, Paris, France; INSERM, UMR_S 938, Université Pierre et Marie Curie, Paris, France. Electronic address: franck.boccara@aphp.fr. · Service de Cardiologie, Hôpital Saint-Antoine (AP-HP), Paris 06 - Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. ·Rev Esp Cardiol (Engl Ed) · Pubmed #27553286.

ABSTRACT: -- No abstract --

6 Editorial Have we forgotten? Oral Manifestations of Kaposi's Sarcoma. 2015

Wild, Richard / Balmer, Mary Colette. ·Liverpool Dental Hospital, Royal Liverpool and Broadgreen University Hospitals, Liverpool, UK. ·Sex Transm Infect · Pubmed #26126530.

ABSTRACT: -- No abstract --

7 Editorial Old case, new leads: miRNA links Kaposi's sarcoma-associated herpesvirus with sepsis. 2014

Lu, W-T / Bushell, M. ·MRC Toxicology Unit, Hodgkin Building, Leicester, UK. ·Cell Death Dis · Pubmed #25476908.

ABSTRACT: -- No abstract --

8 Editorial A seat at the big table: expanding the role of dermatology at the World Health Organization and beyond. 2014

Freeman, Esther E. ·Harvard Medical School, Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: eefreeman@partners.org. ·J Invest Dermatol · Pubmed #25318423.

ABSTRACT: -- No abstract --

9 Editorial Broader implications of a stage-guided stratified therapeutic approach for AIDS-related Kaposi's sarcoma. 2014

Krell, Jonathan / Stebbing, Justin. ·Imperial College London, London, United Kingdom. ·J Clin Oncol · Pubmed #24378412.

ABSTRACT: -- No abstract --

10 Editorial Abecedarium: who am I? K'…. 2014

Werner, A / McGill, I / Laccourreye, O. ·8, rue de la Ferme, 92200 Neuilly-sur-Seine, France. · Place du Plâtre, 69930 Saint-Laurent-de-Chamousset, France. · Université Paris Descartes Sorbonne Paris Cité, Service d'oto-rhino-laryngologie et de chirurgie cervico-faciale, Hôpital européen Georges Pompidou, AP-HP, 20, rue Leblanc, 75908 Paris cedex 15, France. Electronic address: ollivier.laccourreye@egp.aphp.fr. ·Eur Ann Otorhinolaryngol Head Neck Dis · Pubmed #24275326.

ABSTRACT: -- No abstract --

11 Editorial Towards a better understanding of Kaposi sarcoma-associated immune reconstitution inflammatory syndrome. 2013

Ablanedo-Terrazas, Yuria / Alvarado-De La Barrera, Claudia / Reyes-Terán, Gustavo. · ·AIDS · Pubmed #24047765.

ABSTRACT: -- No abstract --

12 Editorial Co-infection: new battlegrounds in HIV/AIDS. 2013

Anonymous4070762. · ·Lancet Infect Dis · Pubmed #23809216.

ABSTRACT: -- No abstract --

13 Editorial [Classification of vascular anomalies]. 2013

Dompmartin, A. · ·Ann Dermatol Venereol · Pubmed #23663704.

ABSTRACT: -- No abstract --

14 Editorial Editorial comment re: Penile Kaposis sarcoma in the state of California. 2012

Hegarty, Paul K. · ·Can J Urol · Pubmed #22512962.

ABSTRACT: -- No abstract --

15 Editorial Cell-free DNA as a biomarker in the context of cancer, viruses, and methylation. 2012

Stebbing, Justin / Bower, Mark. · ·J Infect Dis · Pubmed #22357695.

ABSTRACT: -- No abstract --

16 Editorial Challenges for conducting clinical trials for AIDS malignancies in resource-limited settings. 2011

Mitsuyasu, Ronald. · ·Curr Opin Oncol · Pubmed #21788896.

ABSTRACT: -- No abstract --

17 Editorial Human herpesvirus 8 seropositivity in rural Uganda: maturation of sero-epidemiological studies. 2011

Mbulaiteye, Sam M / Goedert, James J. · ·J Infect Dis · Pubmed #21273189.

ABSTRACT: -- No abstract --

18 Editorial Efforts to counteract locally the effects of systemic immunosupression: a review on the use of imiquimod, a topical immunostimulator in organ transplant recipients. 2010

Trakatelli, M / Katsanos, G / Ulrich, C / Kalabalikis, D / Sotiriadis, D / Stockfleth, E. · ·Int J Immunopathol Pharmacol · Pubmed #20646334.

ABSTRACT: The potent systemic immunosuppression therapy necessary to sustain a life-saving solid organ transplant is associated with an increased incidence of various infections including human papillomavirus infection and skin cancers in organ transplant recipients. Imiquimod, a topical agent that functions through local induction of a specific anti-viral or anti-tumor immune response, appears to be a promising therapeutic option that could potentially counteract in situ the effects of systemic immunosupression in this vulnerable group. Up-to-date studies using this local immune-response modifier in transplanted patients have yielded reassuring and encouraging results regarding its safety and efficacy in this population. However, in order to establish the use of imiquimod as a standard treatment option for organ transplant recipients, additional research and clinical trials are required.

19 Editorial Reconstitution of immune responses against Kaposi sarcoma-associated herpesvirus. 2010

Flores, Roberto / Goedert, James J. · ·AIDS · Pubmed #20616696.

ABSTRACT: -- No abstract --

20 Editorial Editorial commentary: treatment of Kaposi sarcoma in the highly active antiretroviral therapy era. 2008

Dupin, N / Del Giudice, P. · ·Clin Infect Dis · Pubmed #18582204.

ABSTRACT: -- No abstract --

21 Editorial Transmission of Kaposi sarcoma-associated herpesvirus in sub-Saharan Africa. 2008

Mbulaiteye, Sam M / Goedert, James J. · ·AIDS · Pubmed #18301068.

ABSTRACT: -- No abstract --

22 Review [Replication Machinery of Kaposi's Sarcoma-associated Herpesvirus and Drug Discovery Research]. 2019

Watanabe, Tadashi / Fujimuro, Masahiro. ·Department of Cell Biology, Kyoto Pharmaceutical University. ·Yakugaku Zasshi · Pubmed #30606932.

ABSTRACT: Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and Castleman's disease. While liposomal doxorubicin has been used as an effective treatment for KS patients, the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen used for PEL patients was reported to have 1-year survival rates of less than 40%. Moreover, the development of anti-KSHV drugs inhibiting viral replication has been delayed. KSHV establishes a lifelong infection in its host and alternates between a "latent infection" and "lytic infection" state. Latent infection is associated with maintenance of the viral genome and transformation of the infected cells. Lytic infection is the process of producing infectious virus. Elucidating the KSHV life cycle and viral replication machinery is essential for developing novel therapeutic approaches and identifying potential drug targets. To tackle these issues, we have been screening for anti-PEL compounds using PEL-derived cell lines and utilizing recombinant KSHV for functional analysis of KSHV coding genes. In particular, we have focused on the "viral pre-initiation complex" of KSHV and determined its molecular mechanism. The coding proteins conserved among β- and γ-herpesviruses form a complex, which has functional homology with the pre-initiation complex of host cells. The complex is indispensable for the expression of viral proteins composing virus particles. This review summarizes the pathogenesis and therapies of KSHV-associated malignancies. Furthermore, we introduce our recent data on KSHV ORF34, which contributes to viral late gene expression via the formation of the viral pre-initiation complex.

23 Review Skin Cancer and Immunosuppression. 2019

Collins, Lindsey / Quinn, Andrew / Stasko, Thomas. ·Department of Dermatology, The University of Oklahoma Health Sciences Center, 619 Northeast 13th Street, Oklahoma City, OK 73104, USA. Electronic address: Lindsey-collins@ouhsc.edu. · Department of Dermatology, The University of Oklahoma Health Sciences Center, 619 Northeast 13th Street, Oklahoma City, OK 73104, USA. ·Dermatol Clin · Pubmed #30466691.

ABSTRACT: Immunosuppressed patients are at significantly increased risk of developing cutaneous malignancies. These malignancies are often more aggressive compared with the general population and require multidisciplinary care. This article highlights the incidence and risk factors of cutaneous malignancies in this cohort. The treatment and prevention strategies are discussed. There continues to be a need for evidence-driven guidelines regarding the management of skin cancers in these patients.

24 Review Primary effusion lymphoma of the pleural space: Report of a rare complication of cardiac transplant with review of the literature. 2019

Kugasia, Irfan Ali R / Kumar, Arun / Khatri, Akshay / Saeed, Faisal / Islam, Humayun / Epelbaum, Oleg. ·Division of Pulmonary, Critical Care, and Sleep Medicine, Westchester Medical Center, Valhalla, New York. · Department of Internal Medicine, Westchester Medical Center, Valhalla, New York. · Department of Pathology, Westchester Medical Center, Valhalla, New York. ·Transpl Infect Dis · Pubmed #30276937.

ABSTRACT: Primary effusion lymphoma (PEL) is a rare mature B-cell non-Hodgkin's lymphoma arising in body cavities and presenting with effusions. It has been described predominantly in patients with impaired immunity from the acquired immunodeficiency syndrome and is associated with the Human Herpesvirus-8 (HHV-8). Seldom has PEL been diagnosed in persons negative for the human immunodeficiency virus (HIV), and in such cases it has occurred primarily in the setting of posttransplant immunosuppression. We report an instructive case of a Caribbean-American HIV-negative orthotopic heart transplant recipient with a history of HHV-8-associated Kaposi's sarcoma who developed HHV-8 viremia and PEL of the pleural space early in the posttransplant course. This case highlights the importance of considering PEL in the differential diagnosis of a new pleural effusion in a transplant recipient at risk for HHV-8-associated disease.

25 Review Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review. 2019

Charpentier, Chloé / Delyon, Julie / Glotz, Denis / Peraldi, Marie-Noelle / Rerolle, Jean-Philippe / Barrou, Benoît / Ducroux, Emilie / Coilly, Audrey / Legeai, Camille / Barete, Stéphane / Lebbé, Céleste. ·APHP Department of Dermatology, Saint Louis Hospital, Paris, France. · INSERM U976, France. · Paris Diderot University, Sorbonne Paris Cité, France. · Department of Nephrology, Saint Louis Hospital, Paris, France. · Department of Nephrology, Dupuytren Hospital, Limoges, France. · UPMC, Department of Urology, Nephrology and Transplantation, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. · Department of Dermatology, Edouard Herriot Hospital, Lyon, France. · Department of Hepatology and Gastrology, Paul Brousse Hospital, Villejuif, France. · Biomedicine Agency. Saint-Denis La Plaine, France. · UPMC, Unit of Dermatology, Pitié-Salpêtrière Hospital, Sorbonne University, Paris, France. ·Transplantation · Pubmed #30273235.

ABSTRACT: BACKGROUND: Kaposi sarcoma is a vascular tumor related to herpesvirus-8 and is promoted by immunosuppression. For the last 15 years, human immunodeficiency virus (HIV) patients have had access to organ transplantation. The dual immunosuppression of HIV and immunosuppressive treatments might increase the risk and severity of Kaposi sarcoma. METHODS: We conducted a multicentric retrospective study by collecting cases from French databases and society members of transplanted patients, among which 7 HIV-infected patients who subsequently developed Kaposi sarcoma were included. RESULTS: In the CRISTAL database (114 511 patients) and the DIVAT (Données Informatisées et VAlidées en Transplantation) database (19 077 patients), the prevalence of Kaposi sarcoma was 0.18% and 0.46%, respectively, in transplanted patients; these values compare with 0.66% and 0.50%, respectively, in transplanted patients with HIV. The median time from HIV infection to Kaposi sarcoma was 20 years. Kaposi sarcoma occurred during the first year after transplantation in most cases, whereas HIV viral load was undetectable. Only 2 patients had visceral involvement. Five patients were treated with conversion of calcineurin inhibitor to mammalian target of rapamycin inhibitor, and 5 patients were managed by decreasing immunosuppressive therapies. At 1 year, 4 patients had a complete response, and 3 had a partial response. CONCLUSIONS: In our study, Kaposi sarcoma in transplanted patients with HIV did not show any aggressive features and was treated with the usual posttransplant Kaposi sarcoma management protocol.

Next